Sign up to save your podcasts
Or
Share Experts Talk CLL #10 : Let's Talk Sequencing: Where are we now?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Experts Talk CLL #10 : Let's Talk Sequencing: Where are we now?
A discussion between Dr. Peter Anglin and Dr. William G. Wierda (November 2022)
Dr. Anglin and Dr. Wierda discuss sequencing and factors that drive decisions when initiating treatment and when transitioning from one line of therapy to the next. The discussion zooms in on emerging approaches, their benefits over established treatments and their potential role in the CLL treatment algorithm. The relevance of disease characteristics and prognostic risk factors were summarized, as well as patient-related considerations, in the context of treatment duration (continuous vs fixed), duration of response, and treatment-related toxicities.
Peter Anglin, MD, FRCPC, MBA, Hematologist/Oncologist, Physician Lead, Stronach Regional Cancer, Centre Newmarket, ON
William G. Wierda, MD, PhD, Professor and Medical Director, Department of Leukemia, Executive Medical Director, Leukemia, Lymphoma and Stem Cell Transplant, University of Texas, MD Anderson Cancer Centre
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.
View all episodes
By Various Topics on AML and CLL ManagementA discussion between Dr. Peter Anglin and Dr. William G. Wierda (November 2022)
Dr. Anglin and Dr. Wierda discuss sequencing and factors that drive decisions when initiating treatment and when transitioning from one line of therapy to the next. The discussion zooms in on emerging approaches, their benefits over established treatments and their potential role in the CLL treatment algorithm. The relevance of disease characteristics and prognostic risk factors were summarized, as well as patient-related considerations, in the context of treatment duration (continuous vs fixed), duration of response, and treatment-related toxicities.
Peter Anglin, MD, FRCPC, MBA, Hematologist/Oncologist, Physician Lead, Stronach Regional Cancer, Centre Newmarket, ON
William G. Wierda, MD, PhD, Professor and Medical Director, Department of Leukemia, Executive Medical Director, Leukemia, Lymphoma and Stem Cell Transplant, University of Texas, MD Anderson Cancer Centre
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.